as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 19 Nov 2026
₹7.1
Change
-0.08 (-1.11%)
Open
₹7.49
Prev. Close
₹7.18
Day High
₹7.49
Day Low
₹7.05
Volume Analysis
Traded
25,630
Delivered
17,743
Delivery %
69.23%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (1)
- •Promoter holding is rising
Weaknesses (3)
- •Low return on equity (5.83%)
- •Below-average fundamentals quality score (49/100)
- •Low operating margin (3.9%)
Opportunities (0)
No signal for this stock
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹7.81 | ₹7.65 | ₹7.37 | ₹7.21 | ₹6.93 | ₹6.77 | ₹6.49 |
| Fibonacci | ₹7.65 | ₹7.48 | ₹7.38 | ₹7.21 | ₹7.04 | ₹6.94 | ₹6.77 |
| Camarilla | ₹7.22 | ₹7.18 | ₹7.14 | ₹7.21 | ₹7.06 | ₹7.02 | ₹6.98 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
-16.86%
1 Week
+0.71%
1 Month
-3.14%
3 Months
-11.14%
6 Months
+1.43%
1 Year
-26.73%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹6.08
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
5.86%
Net margin 3.7% × asset turnover 0.89x × equity multiplier 1.78x
Company Overview
Sector
Healthcare
Market Cap
₹95 Cr
P/E (TTM)
21.4
ROE
5.83%
Book Value
₹5.3
Face Value
₹2.0
Source: Screener.in (Consolidated figures) — data as of 15 Nov 2026. Not investment advice.
TopFund Analysis
Vaishali Pharma Limited scores weakly on TopFund's composite fundamentals check within the Healthcare sector, at 49/100. The strongest factor is Financial Strength (100/100), while Cash Flow (0/100) is the weakest area to weigh before deciding. Notably: Promoter holding is rising; low return on equity (5.83%); below-average fundamentals quality score (49/100).
TopFund Score — Fundamentals Quality
49/100 — WeakData confidence: 71/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 19 Nov 2026 · How we calculate this →
Financial Strength
Valuation
Cash Flow
Corporate Governance
Momentum
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- −Promoter holding is low: 31.6%
- −Earnings include an other income of Rs.3.57 Cr.
- −Company has high debtors of 170 days.
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Vaishali Pharma reports no deviation in Rs. 9.08 crore preferential issue proceeds for quarter ended 30 September 2026.
Board appointed two independent directors on 5 Nov 2026 and deferred preferential issue proposal.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Sales + | 33 | 25 | 27 | 23 |
| Expenses + | 32 | 23 | 27 | 21 |
| Operating Profit | 1 | 2 | 0 | 1 |
| OPM % | 4.16% | 6.33% | -0.74% | 6.51% |
| Other Income + | 1 | 1 | 1 | 1 |
| Interest | 0 | 1 | 1 | 0 |
| Depreciation | 0 | 0 | 0 | 0 |
| Profit before tax | 2 | 2 | 0 | 2 |
| Tax % | 28.31% | 28.18% | -61.11% | 13.87% |
| Net Profit + | 1 | 1 | 0 | 2 |
| EPS in Rs | 0 | 0 | 0 | 0 |
| Raw PDF | — | — | — | — |
| YoY Sales growth | — | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2026 | TTM | |
|---|---|---|
| Sales + | 109 | 108 |
| Expenses + | 105 | 104 |
| Operating Profit | 4 | 4 |
| OPM % | 3.8% | 3.9% |
| Other Income + | 4 | 4 |
| Interest | 2 | 2 |
| Depreciation | 1 | 1 |
| Profit before tax | 5 | 5 |
| Tax % | 25.0% | — |
| Net Profit + | 4 | 4 |
| EPS in Rs | 0 | 0 |
| Dividend Payout % | 0.0% | — |
| Sales growth | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2026 | |
|---|---|
| Reserves | 43 |
| Borrowings + | 19 |
| Other Liabilities + | 35 |
| Total Liabilities | 123 |
| Fixed Assets + | 2 |
| CWIP | 0 |
| Investments | 6 |
| Other Assets + | 116 |
| Total Assets | 123 |
| Equity Capital | 26 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2026 | |
|---|---|
| Cash from Operating Activity + | 0 |
| Cash from Investing Activity + | -5 |
| Cash from Financing Activity + | 5 |
| Net Cash Flow | 0 |
| Free Cash Flow | 0 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 22 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 73.38% | 73.68% | 73.68% | 73.67% | 73.68% | 73.68% | 73.68% | 73.68% | 68.39% | 68.39% | 68.39% | 68.39% |
| Promoters | 26.62% | 26.32% | 26.32% | 26.32% | 26.32% | 26.32% | 26.32% | 26.32% | 31.61% | 31.61% | 31.61% | 31.61% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Vaishali Pharma Limited (this stock) | 95 | 21.4 | 1.33 | 5.83% |
| Alpa Laboratories Ltd | 109 | 52.0 | 0.59 | 8.38% |
| Sunil Healthcare Ltd. | 78 | 26.6 | 1.03 | 6.01% |
| Parnax Lab Ltd. | 125 | 14.6 | 1.27 | 14.2% |
| Bal Pharma Ltd. | 135 | 17.1 | 1.58 | 7.79% |
| Natural Capsules Limited | 144 | — | 0.66 | -9.45% |
| Mangalam Drug & Chem Ltd | 45 | — | 0.51 | -35.3% |
Which Mutual Funds Hold Vaishali Pharma Limited?
Frequently Asked Questions about Vaishali Pharma Limited
Vaishali Pharma Limited (VAISHALI) closed at ₹7.1 on NSE on 19 November 2026, down 0.08 (1.11%) from the previous close.
Vaishali Pharma Limited trades on the NSE (National Stock Exchange of India) under the symbol VAISHALI.
Vaishali Pharma Limited has a trailing twelve-month P/E (price-to-earnings) ratio of 21.4.
Vaishali Pharma Limited has a dividend yield of 0.0%.
Vaishali Pharma Limited's 52-week high is ₹9.87 and its 52-week low is ₹4.75.
Vaishali Pharma Limited has a market capitalisation of ₹95 crore.
Vaishali Pharma Limited has a TopFund Quality Score of 49/100 (Weak), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Vaishali Pharma Limited?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.